{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:10:00Z","timestamp":1782396600463,"version":"3.54.5"},"posted":{"date-parts":[[2025,7,11]]},"group-title":"Oncology","reference-count":84,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,7,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Ide-cel and cilta-cel are the two FDA-approved anti-BCMA CAR T cell therapies for the treatment of relapsed\/refractory multiple myeloma. Here, we studied a patient who was initially treated with ide-cel with progressive disease and subsequently treated with cilta-cel with a complete response. To elucidate the underlying mechanisms underpinning the distinct clinical outcomes, we conducted multimodal, cross-tissue, and longitudinal single-cell analyses. This enabled us to directly compare the specific cellular and molecular factors distinguishing these two CAR therapies including their cell phenotypes, post-infusion kinetics, and endogenous immune landscapes. We found that the ide-cel infusion product was dominated by CD4\n                  <jats:sup>+<\/jats:sup>\n                  CAR T cells, upregulated a terminal effector phenotype, and exhibited elevated activation signatures. Post-infusion, ide-cel CAR T cells failed to proliferate, sustain cytotoxicity, or migrate into the bone marrow, resulting in persistent myeloma cells and dysregulated monocytes and natural killer cells. In contrast, the cilta-cel infusion product exhibited a balanced ratio of CD4\n                  <jats:sup>+<\/jats:sup>\n                  and CD8\n                  <jats:sup>+<\/jats:sup>\n                  CAR T cells, upregulated a resident memory-like signature, and displayed signatures of IL-1 and IL-2 family cytokine signaling. Post-infusion, cilta-cel CAR T cells retained their resident memory-like profile, were durably retained in the peripheral blood, and successfully infiltrated the bone marrow, leading to effective tumor clearance and reestablishment of immune homeostasis. Our results present important clinical evidence that cilta-cel can serve as an effective salvage treatment following ide-cel failure. By providing a direct patient-matched comparison between two CAR therapies, our study uncovers important insights into both CAR T-cell intrinsic properties and immune environmental factors that contribute to effective BCMA CAR T-cell treatment.\n                <\/jats:p>","DOI":"10.1101\/2025.07.10.25331322","type":"posted-content","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T22:25:13Z","timestamp":1752272713000},"source":"Crossref","is-referenced-by-count":0,"title":["Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses"],"prefix":"10.64898","author":[{"given":"Tony","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Asby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mckenzie","family":"Schubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025071404200441000_2025.07.10.25331322v1.1","first-page":"1","article-title":"Multiple myeloma","volume":"10","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025071404200441000_2025.07.10.25331322v1.2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022806"},{"key":"2025071404200441000_2025.07.10.25331322v1.3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"2025071404200441000_2025.07.10.25331322v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"2025071404200441000_2025.07.10.25331322v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2025071404200441000_2025.07.10.25331322v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2025071404200441000_2025.07.10.25331322v1.7","doi-asserted-by":"crossref","unstructured":"Chekol Abebe, E. , Yibeltal Shiferaw, M. , Tadele Admasu, F. & Asmamaw Dejenie, T. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol 13, 991092 (2022).","DOI":"10.3389\/fimmu.2022.991092"},{"key":"2025071404200441000_2025.07.10.25331322v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02496-0"},{"key":"2025071404200441000_2025.07.10.25331322v1.9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison","volume":"40","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025071404200441000_2025.07.10.25331322v1.10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma","volume":"43","year":"2025","journal-title":"JCO"},{"key":"2025071404200441000_2025.07.10.25331322v1.11","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study","volume":"9","year":"2025","journal-title":"Hemasphere"},{"key":"2025071404200441000_2025.07.10.25331322v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9"},{"key":"2025071404200441000_2025.07.10.25331322v1.13","first-page":"750","article-title":"ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed\/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy","volume":"30","year":"2024","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"2025071404200441000_2025.07.10.25331322v1.14","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.matt.2021.09.027","article-title":"Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents","volume":"4","year":"2021","journal-title":"Matter"},{"key":"2025071404200441000_2025.07.10.25331322v1.15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2019-127309","article-title":"Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b\/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and\/or Refractory Multiple Myeloma (R\/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset","volume":"134","year":"2019","journal-title":"Blood"},{"key":"2025071404200441000_2025.07.10.25331322v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2025071404200441000_2025.07.10.25331322v1.17","doi-asserted-by":"crossref","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest 132, (2022).","DOI":"10.1172\/JCI150807"},{"key":"2025071404200441000_2025.07.10.25331322v1.18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"2025071404200441000_2025.07.10.25331322v1.19","doi-asserted-by":"crossref","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025071404200441000_2025.07.10.25331322v1.20","doi-asserted-by":"crossref","unstructured":"Qiu, Z. , Chu, T. H. & Sheridan, B. S . TGF-\u03b2: Many Paths to CD103+ CD8 T Cell Residency. Cells 10, 989 (2021).","DOI":"10.3390\/cells10050989"},{"key":"2025071404200441000_2025.07.10.25331322v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.019"},{"key":"2025071404200441000_2025.07.10.25331322v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986"},{"key":"2025071404200441000_2025.07.10.25331322v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02339-4"},{"key":"2025071404200441000_2025.07.10.25331322v1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y"},{"key":"2025071404200441000_2025.07.10.25331322v1.25","doi-asserted-by":"crossref","first-page":"e003293","DOI":"10.1136\/jitc-2021-003293","article-title":"Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025071404200441000_2025.07.10.25331322v1.26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181218"},{"key":"2025071404200441000_2025.07.10.25331322v1.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201150"},{"key":"2025071404200441000_2025.07.10.25331322v1.28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg8764"},{"key":"2025071404200441000_2025.07.10.25331322v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0311-z"},{"key":"2025071404200441000_2025.07.10.25331322v1.30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1276"},{"key":"2025071404200441000_2025.07.10.25331322v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7"},{"key":"2025071404200441000_2025.07.10.25331322v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2025071404200441000_2025.07.10.25331322v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3322"},{"key":"2025071404200441000_2025.07.10.25331322v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.012"},{"key":"2025071404200441000_2025.07.10.25331322v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/nature24993"},{"key":"2025071404200441000_2025.07.10.25331322v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2745"},{"key":"2025071404200441000_2025.07.10.25331322v1.37","doi-asserted-by":"crossref","unstructured":"Jung, I.-Y. et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep Med 4, 101053 (2023).","DOI":"10.1016\/j.xcrm.2023.101053"},{"key":"2025071404200441000_2025.07.10.25331322v1.38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s43018-024-00768-3","article-title":"Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling","volume":"5","year":"2024","journal-title":"Nat Cancer"},{"key":"2025071404200441000_2025.07.10.25331322v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59298-w"},{"key":"2025071404200441000_2025.07.10.25331322v1.40","doi-asserted-by":"crossref","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12, 868 (2021).","DOI":"10.1038\/s41467-021-21177-5"},{"key":"2025071404200441000_2025.07.10.25331322v1.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439"},{"key":"2025071404200441000_2025.07.10.25331322v1.42","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.15.593193"},{"key":"2025071404200441000_2025.07.10.25331322v1.43","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.23.25325569"},{"key":"2025071404200441000_2025.07.10.25331322v1.44","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2025071404200441000_2025.07.10.25331322v1.45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/iid3.53","article-title":"The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma","volume":"3","year":"2015","journal-title":"Immun Inflamm Dis"},{"key":"2025071404200441000_2025.07.10.25331322v1.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023529"},{"key":"2025071404200441000_2025.07.10.25331322v1.47","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","year":"2024","journal-title":"Blood Advances"},{"key":"2025071404200441000_2025.07.10.25331322v1.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848"},{"key":"2025071404200441000_2025.07.10.25331322v1.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025071404200441000_2025.07.10.25331322v1.50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)","volume":"142","year":"2023","journal-title":"Blood"},{"key":"2025071404200441000_2025.07.10.25331322v1.51","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2024-211410","article-title":"Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma","volume":"144","year":"2024","journal-title":"Blood"},{"key":"2025071404200441000_2025.07.10.25331322v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2025071404200441000_2025.07.10.25331322v1.53","doi-asserted-by":"crossref","unstructured":"Watanabe, N. , Mo, F. & McKenna, M. K . Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol 13, 876339 (2022).","DOI":"10.3389\/fimmu.2022.876339"},{"key":"2025071404200441000_2025.07.10.25331322v1.54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820"},{"key":"2025071404200441000_2025.07.10.25331322v1.55","doi-asserted-by":"crossref","unstructured":"Depew, C. E. , Rixon, J. A. & McSorley, S. J . Optimal generation of hepatic tissue-resident memory CD4 T cells requires IL-1 and IL-2. Proc Natl Acad Sci U S A 120, e2214699120.","DOI":"10.1073\/pnas.2214699120"},{"key":"2025071404200441000_2025.07.10.25331322v1.56","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/s41385-018-0017-4","article-title":"IL-1\u03b2 as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses","volume":"11","year":"2018","journal-title":"Mucosal Immunol"},{"key":"2025071404200441000_2025.07.10.25331322v1.57","doi-asserted-by":"crossref","unstructured":"Zhang, D. K. Y. et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun 14, 506 (2023).","DOI":"10.1038\/s41467-023-36126-7"},{"key":"2025071404200441000_2025.07.10.25331322v1.58","doi-asserted-by":"crossref","unstructured":"Sanoyan, D. A. et al. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients. BMC Cancer 23, 345 (2023).","DOI":"10.1186\/s12885-023-10824-3"},{"key":"2025071404200441000_2025.07.10.25331322v1.59","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0405"},{"key":"2025071404200441000_2025.07.10.25331322v1.60","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1677"},{"key":"2025071404200441000_2025.07.10.25331322v1.61","unstructured":"Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma. | Journal of Clinical Oncology. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2021.39.15_suppl.7558."},{"key":"2025071404200441000_2025.07.10.25331322v1.62","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012563"},{"key":"2025071404200441000_2025.07.10.25331322v1.63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004483"},{"key":"2025071404200441000_2025.07.10.25331322v1.64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","year":"2021","journal-title":"Blood"},{"key":"2025071404200441000_2025.07.10.25331322v1.65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","year":"2016","journal-title":"Br J Haematol"},{"key":"2025071404200441000_2025.07.10.25331322v1.66","unstructured":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study - PMC. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11735948\/#hem370070-sec-0110."},{"key":"2025071404200441000_2025.07.10.25331322v1.67","first-page":"1","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025071404200441000_2025.07.10.25331322v1.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00772-9"},{"key":"2025071404200441000_2025.07.10.25331322v1.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2025071404200441000_2025.07.10.25331322v1.70","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4380"},{"key":"2025071404200441000_2025.07.10.25331322v1.71","unstructured":"Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun 8, 14049 (2017)."},{"key":"2025071404200441000_2025.07.10.25331322v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"2025071404200441000_2025.07.10.25331322v1.73","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0619-0"},{"key":"2025071404200441000_2025.07.10.25331322v1.74","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118"},{"key":"2025071404200441000_2025.07.10.25331322v1.75","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr260"},{"key":"2025071404200441000_2025.07.10.25331322v1.76","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-023-06816-9"},{"key":"2025071404200441000_2025.07.10.25331322v1.77","unstructured":"ComplexHeatmap. Bioconductor http:\/\/bioconductor.org\/packages\/ComplexHeatmap\/."},{"key":"2025071404200441000_2025.07.10.25331322v1.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0336-210.1038\/s41596-020-0336-2"},{"key":"2025071404200441000_2025.07.10.25331322v1.79","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4463"},{"key":"2025071404200441000_2025.07.10.25331322v1.80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: An R-based toolkit for single-cell immune receptor analysis","volume":"9","year":"2020","journal-title":"F1000Res"},{"key":"2025071404200441000_2025.07.10.25331322v1.81","doi-asserted-by":"crossref","unstructured":"Morabito, S. , Reese, F. , Rahimzadeh, N. , Miyoshi, E. & Swarup, V . hdWGCNA identifies co-expression networks in high-dimensional transcriptomics data. Cell Rep Methods 3, 100498 (2023).","DOI":"10.1016\/j.crmeth.2023.100498"},{"key":"2025071404200441000_2025.07.10.25331322v1.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01468-y"},{"key":"2025071404200441000_2025.07.10.25331322v1.83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30755-0"},{"key":"2025071404200441000_2025.07.10.25331322v1.84","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02186-3"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.07.10.25331322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:40:33Z","timestamp":1768509633000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.07.10.25331322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":84,"URL":"https:\/\/doi.org\/10.1101\/2025.07.10.25331322","relation":{},"subject":[],"published":{"date-parts":[[2025,7,11]]},"subtype":"preprint"}}